Dr. Reddy's acquires Mayne Pharma's US prescription portfolio for $105 mn

by IANS |

Chennai, Feb 27 (IANS) Indian pharma major, Dr. Reddy's Laboratories Ltd, through its subsidiary has inked an agreement to acquire the US generic prescription product portfolio of the Australia-based, Mayne Pharma Group Limited, for consideration of about $105 million.

According to Dr. Reddy's, $90 million will be paid upfront in cash and there will be contingent payments of up to $15 million, towards inventory and credits for certain accrued channel liabilities to be determined on the closing date.

The Indian company said the acquired portfolio of the drugs include 45 commercial products, four pipeline products and 40 approved non-marketed products, including a number of generic products focused on women's health.

For the financial period ended June 30, 2022, Mayne Pharma reported a total revenue of $111 million for the acquired portfolio.

The value of total addressable market for the pipeline and approved non-marketed products in the US is nearly $3.6 billion for the calendar year ending in December 2022 according to IQVIA, Dr. Reddy's said.

Approved high-value products include a hormonal vaginal ring, a birth control pill and a cardiovascular product.

The closing of the transaction is subject to satisfactory completion of customary closing conditions, including the applicable waiting period, under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act), as amended.

"This important acquisition provides our North America organisation with a significant foothold in the women's health space. The acquisition is in line with our stated strategy to enhance our portfolio in our chosen growth markets. We are well-positioned to successfully integrate the portfolio and grow the business," said Marc Kikuchi, Chief Executive Officer, North America business, Dr. Reddy's.

Latest News
Gary Stead points out New Zealand losing Tests to England last year as missed chance for not defending WTC title Thu, Mar 23, 2023, 04:05 PM
China's smartwatch shipments fell by 9.3% in 2022: Report Thu, Mar 23, 2023, 03:53 PM
Now sync your air travel with Uber via email integration in India Thu, Mar 23, 2023, 03:52 PM
Aus zoo welcomes 1st southern white rhino calf born in decade Thu, Mar 23, 2023, 03:49 PM
Iranian, Saudi FMs hold phone talks, agree to meet soon Thu, Mar 23, 2023, 03:48 PM
Dhanbad: 4 dead, many injured as coal mine caves in during illegal mining Thu, Mar 23, 2023, 03:43 PM
Maha Congress protests against jail sentence for Rahul Thu, Mar 23, 2023, 03:41 PM
KCR announces Rs 10,000 per acre compensation for crop losses Thu, Mar 23, 2023, 03:40 PM
Vietnam aims to end malaria with more funding Thu, Mar 23, 2023, 03:13 PM
BJP MLA Vijender Gupta moves HC challenging his suspension from Delhi Assembly Thu, Mar 23, 2023, 03:01 PM
Govt afraid of Rahul Gandhi, conspiring to disqualify him from LS: Congress Thu, Mar 23, 2023, 02:41 PM
Honour killing in TN: CM assures Assembly of stringent action Thu, Mar 23, 2023, 02:36 PM
Imran claims another assassination plot Thu, Mar 23, 2023, 02:34 PM
Will appeal in higher court against Rahul's conviction: Kharge Thu, Mar 23, 2023, 01:36 PM
Viveka murder case: Telangana HC adjourns hearing on CBI plea Thu, Mar 23, 2023, 01:34 PM